Alternatives to rivaroxaban
2 same-class SPL records vs rivaroxaban - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.
Brand: Xarelto
How to read a high-report FAERS peer set
rivaroxaban ranks in the upper FAERS-volume third of the corpus (#26 of 524); 2 same-class peers are listed for field comparison only. Labeled indication field for rivaroxaban: This medicine can help prevent strokes in people with an irregular heartbeat called atrial fibrillation.
Top FAERS reaction fields for rivaroxaban total 78,794 reports across 10 reactions, set beside apixaban, edoxaban. Counts are exposure-weighted submissions, not per-patient risk.
About rivaroxaban
Rivaroxaban (Xarelto) is a drug that helps to prevent blood clots from forming. It is used to lower the risk of stroke and treat or prevent dangerous clots in your veins and lungs.
Used for: This medicine can help prevent strokes in people with an irregular heartbeat called atrial fibrillation. It also treats blood clots in the legs (deep vein thrombosis or DVT) and lungs (pulmonary embolism or PE). Rivaroxaban can also lower the risk of these clots coming back. It is also used to prevent blood clots after hip or knee replacement surgery and in acutely ill patients.
2 Direct Oral Anticoagulant (Factor Xa Inhibitor) peers (wide set)
apixaban
RxEliquis
Apixaban is used to lower the chance of stroke in people with an irregular heartbeat called atrial fibrillation. It also prevents blood clots in the legs (deep vein thrombosis or DVT) that can happen after hip or knee replacement surgery. Apixaban is also used to treat DVT and lung clots (pulmonary embolism or PE), and to prevent them from coming back.
edoxaban
RxSavaysa
Savaysa is used to lower the risk of stroke and blood clots in people with nonvalvular atrial fibrillation, a type of irregular heartbeat. It is also used to treat blood clots in the deep veins of your legs (DVT) or in your lungs (PE). You will likely need to take another medicine to prevent blood clots for 5 to 10 days before starting Savaysa for DVT or PE.
rivaroxaban vs apixaban & edoxaban · FAERS reaction fields
FAERS top-reaction field "Gastrointestinal Haemorrhage" shows the widest count spread between rivaroxaban and apixaban, edoxaban in this extract (20,024-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.
| Side Effect | rivaroxaban | apixaban | edoxaban |
|---|---|---|---|
| Gastrointestinal Haemorrhage | 21,559 | 1,535 | - |
| Haemorrhage | 7,714 | - | - |
| Dyspnoea | 7,149 | 3,598 | - |
| Epistaxis | 6,698 | - | - |
| Fatigue | 6,546 | 2,193 | - |
| Death | 6,030 | 2,332 | - |
| Fall | 6,003 | 2,287 | - |
| Pulmonary Embolism | 5,962 | 1,542 | - |
"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.
rivaroxaban FAERS volume vs class peers
FAERS volume band
rivaroxaban is FAERS corpus rank #26 of 524 (high volume tercile). Top-reaction field total: 78,794.
Frequently Asked Questions
Where does rivaroxaban sit in FAERS report volume vs Direct Oral Anticoagulant (Factor Xa Inhibitor) peers? ▼
Registry note: FAERS counts are voluntary reports and do not establish causation or risk rates. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for rivaroxaban: see also the generic vs brand label guide when reading Xarelto SPL strings.
Read our methodology - how this data is sourced, computed, and verified.